Brevan Howard Capital Management’s Viking Therapeutics VKTX Stock Holding History

Brevan Howard Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.14M	Sell	29,259 -676	-2%	-$21.8K	0.01%	993
2026 Q1	$974K	Sell	29,935 -28,012	-48%	-$900K	0.01%	913
2025 Q4	$2.04M	Buy	+57,947	New	+$2.05M	0.02%	482
2025 Q3	–	Sell	-37,574	Closed	-$996K	–	2309
2025 Q2	$996K	Buy	+37,574	New	+$989K	0.01%	1063
2024 Q3	–	Sell	-18,489	Closed	-$980K	–	1461
2024 Q2	$980K	Buy	18,489 +12,013	+186%	+$787K	0.01%	383
2024 Q1	$531K	Buy	+6,476	New	+$288K	﹤0.01%	438

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Brevan Howard Capital Management's VKTX Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Viking Therapeutics (VKTX) stake by 2.3% in Q2 2026, selling an estimated $21.8K and leaving 29,259 shares worth $1.14M. The position accounts for 0.01% of the portfolio, ranked #993.

Brevan Howard Capital Management first reported a position in VKTX in Q1 2024 and has held it in 6 quarters since. The position peaked at $2.04M in Q4 2025. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Brevan Howard Capital Management held 29,259 shares of Viking Therapeutics worth $1.14M as of Q2 2026.
Brevan Howard Capital Management sold 676 Viking Therapeutics shares in Q2 2026, an estimated $21.8K.
Viking Therapeutics made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #993 holding.
Brevan Howard Capital Management first reported a position in Viking Therapeutics in Q1 2024 and has held it in 6 quarters since.
Brevan Howard Capital Management's Viking Therapeutics position peaked at $2.04M in Q4 2025.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.